Business
Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting
Survey conducted in collaboration with the Depression and Bipolar Support Alliance (DBSA) Survey respondents reported persistence of high levels of depressive
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Survey conducted in collaboration with the Depression and Bipolar Support Alliance (DBSA) Survey respondents reported persistence of high levels of depressive symptoms and interference with work and daily functioning despite treatment Respondents reported low levels of hope and high levels of dissatisfaction with current treatments NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the results of the SUPPORT (Studying the Impact of Patient Treatment Experiences on Patient Hope for Future Major Depressive Disorder Pharmacotherapies) survey of 385 patients with depression, demonstrating persistence of high levels of depressive symptoms despite treatment, substantial interference with work and daily life, low levels of patient hope, and high levels of patient dissatisfaction with current treatments. The SUPPORT survey assessed treatment experiences and expectations in patients taking antidepressants for major depressive disorder (MDD). The web-based survey was developed in collaboration with the Depression and Bipolar Support Alliance (DBSA) and the DBSA Peer Council; Roger McIntyre, MD, Professor of Psychiatry and Pharmacology, University of Toronto, Canada and Chair of the DBSA Scientific Advisory Board; and Greg Mattingly, MD, Associate Clinical Professor of Psychiatry at Washington University and President of the Midwest Research Group. The SUPPORT results were presented on June 1, 2022 at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting, held in Scottsdale, Arizona and virtually. “Millions of people in the United States are currently living with depression. There is a critical and urgent need for new and effective treatments, as evidenced by the findings from the SUPPORT survey, for patients experiencing depression,” said Michael Pollock, Chief Executive Officer of the Depression and Bipolar Support Alliance. “The Depression and Bipolar Support Alliance (DBSA) envisions wellness for people living with mood disorders and it is our mission to provide hope, help, support, and education to improve the lives of people who have mood disorders. We are pleased to partner with Axsome to increase support for and empower those e...